![]() | ![]() |
Formats:
|
||||||||||
Copyright © 2007, American Society for Microbiology The TAR Hairpin of Human Immunodeficiency Virus Type 1 Can Be Deleted When Not Required for Tat-Mediated Activation of Transcription Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands *Corresponding author. Mailing address: Laboratory of Experimental Virology, Academic Medical Center, room K3-106, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. Phone: (31-20) 566 3396. Fax: (31-20) 691 6531. E-mail: a.t.das/at/amc.uva.nl Received February 23, 2007; Accepted May 2, 2007. This article has been cited by other articles in PMC.Abstract The human immunodeficiency virus type 1 (HIV-1) RNA genome contains a terminal repeat (R) region that encodes the transacting responsive (TAR) hairpin, which is essential for Tat-mediated activation of gene expression. TAR has also been implicated in several other processes during viral replication, including translation, dimerization, packaging, and reverse transcription. However, most studies in which replication of TAR-mutated viruses was analyzed were complicated by the dominant negative effect of the mutations on transcription. We therefore used an HIV-1 variant that does not require TAR for transcription to reinvestigate the role of TAR in HIV-1 replication. We demonstrate that this virus can replicate efficiently upon complete deletion of TAR. Furthermore, evolution of a TAR-deleted variant in long-term cultures indicates that HIV-1 requires a stable stem-loop structure at the start of the viral transcripts in which the 5′-terminal nucleotides are base paired. This prerequisite for efficient replication can be fulfilled by the TAR hairpin but also by unrelated stem-loop structures. We therefore conclude that TAR has no essential function in HIV-1 replication other than to accommodate Tat-mediated activation of transcription. Retroviral RNA genomes contain a sequence repeat (R) that forms the extreme 5′ and 3′ ends of the viral transcripts. The transacting responsive (TAR) region of the 97-nucleotide (97-nt) R region of human immunodeficiency virus type 1 (HIV-1) RNA can fold a stable hairpin structure (8) (Fig. (Fig.1)1
There have been numerous reports in which additional functions of TAR in translation, dimerization, packaging, and reverse transcription of the viral transcripts have been proposed (reviewed in references 1, 2, 6, and 16). More recently, it has been suggested that TAR may also affect the cellular RNA interference process (3, 4). Thus, a pleiotropy of functions has been attributed to the TAR motif in a variety of experimental systems. The most biologically relevant assay system is that of the replicating virus, and the importance of TAR is underlined by the observation that mutations within TAR cause severe replication defects. However, these studies are complicated by the fact that nearly all mutations in TAR affect the transcription process. This dominant effect on transcription makes it difficult or impossible to distinguish the effect of such mutations on other processes during virus replication. We and others previously reported the construction of an HIV-1 variant that does not depend on the Tat-TAR interaction for activation of transcription (13, 30, 34). In our HIV-rtTA variant, both the Tat protein and its TAR binding site were inactivated by mutation (Fig. (Fig.1A)1A MATERIALS AND METHODS Construction of HIV-rtTA variants. Construction of the HIV-rtTA molecular clone was described previously (13, 34). The HIV-rtTA variant used in this study (HIV-rtTAF86Y A209T2ΔtetO) contains the 2ΔtetO promoter configuration in both the 5′ and 3′ LTR (22) and the optimized rtTAF86Y A209T gene (14). Deletions in TAR were introduced in both the 5′ and 3′ LTRs of the HIV-rtTA plasmid in three steps as described below. Briefly, we first introduced the deletions by PCR mutagenesis in the 3′ LTR of a shuttle vector encompassing the 3′ half of the HIV-rtTA genome, subsequently introduced the mutations in the 5′ LTR of HIV-rtTA, and finally combined the 5′ and 3′ LTR mutated fragments. For the construction of the A variant, the 3′ LTR sequence was amplified with primers tTA-tetO-1 (ctccccgggtaactaagtaaggat; sense primer annealing at the 3′ end of the rtTA gene) and TAR-A (cagagagctcca-Δ-atgctccagagagacccagtacaggc [SacI site underlined, Δ indicating position of deletion]), with plasmid pBlue3′LTRext-ΔU3-rtTAF86Y A209T-2ΔtetO, which includes Env, rtTA, and 3′ LTR sequences of the HIV-rtTA genome (14), as the template. The PCR product was digested with BspEI and SacI and ligated into the corresponding sites of the shuttle vector pBlue3′LTRext-ΔU3-rtTAF86Y A209T-2ΔtetO-mPL, which is a derivative of pBlue3′LTRext-ΔU3-rtTAF86Y A209T-2ΔtetO in which the SacI site has been removed from the vector sequence by digestion with BssHII and BamHI, blunting of the sticky ends with Klenow polymerase and deoxynucleoside triphosphates, and subsequent religation. The C variant was constructed in the same way, but PCR was performed with primers tTA-tetO-1 and TAR-C (cagagagctccaatgctcctttctgg-Δ-cccagtacaggcaaaaagcag). Similarly, for the construction of the B variant, PCR was performed with primers TAR-B (attggagctc-Δ-tagggaacccactgcttaagcc) and pLAI-3′seq (tgtctcatgagcggatacata [antisense primer annealing to vector sequences downstream of 3′ LTR]), and the PCR product was digested with SacI and AatII and subsequently ligated into the corresponding sites of pBlue3′LTRext-ΔU3-rtTAF86Y A209T-2ΔtetO-mPL. The D and F variants were constructed in the same way but with primers TAR-D (attggagctctctgg-Δ-cccactgcttaagcctcaata) and TAR-F (attggagctc-Δ-cccactgcttaagcctcaata), respectively. For construction of the E variant, we used primers tTA-tetO-1 and TAR-E (aggcaagctttattgaggcttaagcagtggg-Δ-cccagtacaggcaaaaagca [HindIII site underlined]), digested the PCR product with BspEI and HindIII, and subsequently ligated this fragment into the corresponding sites of pBlue3′LTRext-ΔU3-rtTAF86Y A209T-2ΔtetO-mPL. For the construction of the double-mutant AB, we combined the A and B deletions. The A variant of pBlue3′LTRext-ΔU3-rtTAF86Y A209T-2ΔtetO-mPL was digested with BamHI and SacI, and the 1,463-bp env-rtTA-LTR fragment was used to replace the corresponding sequences in the B variant of this shuttle vector. Similarly, to combine the C and D deletions in the CD double mutant, the BamHI-SacI env-rtTA-LTR fragment of the C variant was used to replace the corresponding sequences in the D variant. For the introduction of the TAR mutations into the 5′ LTR of HIV-rtTA, we employed PCR to amplify the LTR regions from the pBlue3′LTRext-ΔU3-rtTAF86Y A209T-2ΔtetO-mPL variants A to F with primers U3-Xba-Not (acgtctagagcggccgcactggaagggctaattcactc [positions −331 to −313]) and U5-Nar (ttcgggcgccactgctagagattttccacactg [positions +192 to +160]), digested the PCR product with NotI and NarI, and used this fragment to replace the corresponding 5′ LTR sequences in HIV-rtTA. To construct 5′-plus-3′ TAR-mutated HIV-rtTA variants, the BamHI-BglI fragments of the pBlue3′LTRext-ΔU3-rtTAF86Y A209T-2ΔtetO-mPL variants were used to replace the corresponding Env-rtTA-3′ LTR sequences in the 5′ LTR-mutated HIV-rtTA variants. All mutations were verified by sequence analysis. Proviral DNA analysis and cloning of evolved sequences. Virus-infected cells were pelleted by centrifugation at 4,000 rpm for 4 min and washed with phosphate-buffered saline (PBS). DNA was solubilized by resuspending the cells in 10 mM Tris-HCl (pH 8.0)-0.1 mM EDTA-0.5% Tween 20 followed by incubation with 200 μg of proteinase K per ml at 56°C for 30 min and at 95°C for 10 min. Proviral DNA sequences were PCR amplified from total cellular DNA with primers U3-Xba-Not (acgtctagagcggccgcactggaagggctaattcactc [positions −331 to −313]) and AD-GAG (atggatccgttctagctccctgcttgccc [positions +463 to +442]), ligated into pCR2.1-TOPO TA-cloning vector (Invitrogen), and sequenced with primer BB3 (gagtcctgcgtcgagagagctcctctggtt [positions +245 to +216]). For the cloning of the evolved ER1-3 sequences into the HIV-rtTA provirus, the U3-R sequences were PCR amplified from the corresponding TA clones with primers U3-Xba-Not and AD-GAG. The PCR product was digested with NarI and NotI and used to replace the corresponding 5′ LTR sequences in HIV-rtTA. Moreover, the PCR product was digested with SalI and HindIII and used to replace the corresponding fragment in pBlue3′LTRext-ΔU3-rtTAF86Y A209T-2ΔtetO-mPL. The BamHI-BglI fragments of these 3′ LTR-mutated plasmids were used to replace the corresponding sequences in the 5′ LTR-mutated HIV-rtTA variants, which resulted in HIV-rtTA variants with ER1-3 sequences in both the 5′ and 3′ LTRs. rtTA activity assay. In the plasmid pLTR-2ΔtetO-X/H-lucff the expression of firefly luciferase is under the control of the LTR-2ΔtetO promoter of HIV-rtTA. For the construction of this plasmid, we isolated the XbaI-HindIII fragment encompassing the LTR-2ΔtetO promoter sequences (−333 to +82) of HIV-rtTAF86Y A209T2ΔtetO and ligated this fragment into the compatible NheI and HindIII sites of the luciferase reporter construct pGL3-Basic (Promega). For cloning purposes, the SalI site in pGL3-basic had been removed by digestion with SalI, blunting of the sticky ends with Klenow polymerase and deoxynucleoside triphosphates, and subsequent religation. For the introduction of the TAR mutations into pLTR-2ΔtetO-X/H-lucff, we PCR amplified the LTR region from the pBlue3′LTRext-ΔU3-rtTAF86Y A209T-2ΔtetO-mPL variants A to F with primers U3-Xba-Not and U5-Nar, digested the PCR product with SalI and HindIII, and used this fragment to replace the corresponding sequences in pLTR-2ΔtetO-X/H-lucff. Plasmid pBlue3′LTR-lucff contains the complete U3 region and R sequences up to position +82 of the wild-type HIV-1 LAI proviral DNA coupled to the firefly luciferase reporter gene (19). The plasmid pRL-CMV (Promega), in which the expression of Renilla luciferase is controlled by a cytomegalovirus promoter, is cotransfected into the C33A cells to allow correction for differences in transfection efficiency. C33A cells were cultured in 2-cm2 wells and transfected with 20 ng pLTR-2ΔtetO-lucff construct (TARm and mutants A to F) or 20 ng pBlue3′LTR-lucff (TARwt), 0.4 ng rtTA-expression plasmid pCMV-rtTAF86Y A209T (14), and 0.5 ng pRL-CMV. pBluescript was added to the transfection mix to achieve a total of 1 μg of DNA. The cells were cultured after transfection for 48 h with 0 to 1,000 ng/ml dox (Sigma D-9891). Cells were lysed in passive lysis buffer, and firefly and Renilla luciferase activities were determined with a dual-luciferase assay (Promega). The expression values for firefly and Renilla luciferase were within the linear range, and no squelching effects were observed. The promoter activity was calculated as the ratio between the firefly and Renilla luciferase activities and was corrected for between-session variation (29). Cells and viruses. SupT1 T cells were cultured and transfected by electroporation, as previously described (14). To assay virus replication, 5 × 106 SupT1 cells were transfected with 1 μg of the proviral constructs and cultured in 5 ml medium with 1 μg/ml dox. For the selection of variants with improved replication capacity, the viruses were cultured for up to 168 days. When virus-induced cytopathic effects were observed, high-level virus replication was maintained by passage of the cell-free culture supernatant onto uninfected SupT1 cells. Cell and supernatant samples were stored at −80°C for subsequent analysis. C33A cervix carcinoma cells (ATCC HTB31) were cultured in 2-cm2 wells and transfected with 1 μg HIV-rtTA construct by calcium phosphate precipitation, as previously described (14). Virus production was measured using a CA-p24 enzyme-linked immunosorbent assay (ELISA) and culture medium samples (20). RNA analysis. For the isolation of viral transcripts, C33A cells were cultured in 10-cm2 wells and transfected with 5 μg HIV-rtTA construct. After 48 h, cells were washed with PBS, briefly incubated with 0.5 ml 0.05% trypsin-EDTA (Invitrogen) until cells detached, resuspended in 1 ml 10% fetal bovine serum-containing medium to inactivate trypsin, and subsequently centrifuged at 2,750 × g for 5 min. Cells were washed in 1 ml PBS, centrifuged at 2,750 × g for 5 min, lysed in 0.6 ml RLT buffer (QIAGEN), and homogenized with a QIAshredder column (QIAGEN). Total cellular RNA was isolated with an RNeasy kit (QIAGEN), and contaminating DNA was removed with RNase-free DNase (QIAGEN) during isolation. When indicated, RNA was decapped with tobacco acid pyrophosphatase (BIOzymTC; Epicenter Biotechnologies, Landgraaf, The Netherlands). We used 5′ rapid amplification of cDNA ends (RACE) system version 2.0 (Invitrogen) to analyze the 5′ ends of the RNA transcripts. Briefly, the primer AD-GAG was annealed to the viral RNA at 85°C for 2 min and 70°C for 10 min. The RNA was reverse transcribed with SuperScript II reverse transcriptase (RT; Invitrogen) at 50°C for 50 min. After inactivation of RT at 70°C for 15 min, RNA was degraded with RNase H and RNase T1. The cDNA product was purified with a QIAquick PCR purification kit (QIAGEN) and dA-tailed with terminal deoxynucleotidyl transferase and dATP. After inactivation of terminal deoxynucleotidyl transferase at 65°C for 10 min, the dA-tailed cDNA was amplified by PCR with primers AD-SD (catggatccagtcgcctcccctcgcctc [positions +290 to +270]) and 3′RACE Abridged Primer (ggccacgcgtcgactagtac[t]17) and ligated into pCR2.1 TA-cloning vector. Cloned cDNA fragments were sequenced with primer BB3. RESULTS Deletions in TAR do not affect gene expression. HIV-rtTA carries multiple nucleotide substitutions in TAR (TARm in Fig. Fig.1B)1B To determine the effect of these TAR deletions on gene expression, we made plasmid reporter constructs in which the LTR-tetO promoter of HIV-rtTA, carrying the original TAR sequence (TARm) or a mutated TAR sequence (A to F), was coupled to the luciferase reporter gene. We assayed dox responsiveness of these constructs upon cotransfection with an rtTA-expression plasmid into C33A cervix carcinoma cells (Fig. (Fig.2A).2A
Replication of TAR-deleted variants. To reveal additional roles of TAR in viral replication, we introduced TAR deletions A to F into the HIV-rtTA genome. The TAR sequence is part of the 97-nt R region that is present at both ends of the viral RNA genome and plays an important role in first-strand transfer during reverse transcription (9). Since sequence differences between the 5′ and 3′ R regions may hamper the reverse transcription process, we introduced the TAR mutations at both ends of the proviral genome. We transfected these HIV-rtTA plasmids into C33A cells, which support HIV-1 gene expression and virion production but not HIV-1 infection due to lack of a CD4 receptor. Cells were cultured for 48 h with dox, and we subsequently measured CA-p24 production in the culture supernatant. The TARm and TAR deletion variants all produced a high level of CA-p24 (data not shown), which confirms that viral gene expression is not significantly affected by partial or complete deletion of TAR. We transfected the HIV-rtTA plasmids into the HIV-1-susceptible SupT1 T-cell line to determine the effect of the TAR deletions on viral replication. These cells support efficient replication of the original HIV-rtTA in the presence of dox (Fig. (Fig.2B;2B Improved replication of TAR-deleted HIV-rtTA upon viral evolution. Although the complete removal of the TAR structure does not abolish replication, the E mutant replicates much slower than the original HIV-rtTA (TARm), and we anticipated that this mutant could evolve to a better-replicating variant when cultured for a prolonged period. We therefore started three long-term cultures of the E mutant and passaged the virus onto fresh cells at the peak of infection when massive syncytia were observed. We noticed that the time interval between infection and the appearance of syncytia became shorter upon prolonged culturing, suggesting that the viral replication capacity was improved. Sequence analysis of the proviral genome present in these long-term cultures revealed that the E mutant had acquired multiple nucleotide substitutions, deletions, and insertions at the U3-R boundary in cultures I and II, while part of the R sequence had been duplicated in culture III (Fig. (Fig.3A3A
To demonstrate that these mutations improve viral replication, the sequences that were most abundant in culture I at days 104 and 168 were recloned into the HIV-rtTA proviral genome (variants ER1 and ER2, respectively). Similarly, we recloned the duplicated R sequence observed in culture III at day 97 (variant ER3). Upon transfection of these plasmids into C33A cells, similarly high levels of CA-p24 production were observed with the original construct (TARm), the TAR-deleted E mutant, and the evolved ER1, ER2, and ER3 variants (data not shown). Replication of these HIV-rtTA variants was assayed using the SupT1 T-cell line. The ER1, ER2, and ER3 variants replicated much more efficiently than the E mutant and almost as efficiently as the original HIV-rtTA (TARm) (Fig. (Fig.3B).3B Evolutionary repair of a hairpin structure at the 5′ end of the viral RNA. Transcription of the proviral genome starts at the U3-R boundary in the 5′ LTR promoter. In both wild-type HIV-1 and HIV-rtTA, the 5′ end of the RNA transcript folds the TAR and poly(A) hairpin structures (7), with the 5′ terminal nucleotides being included in the base-paired TAR stem (Fig. (Fig.3C).3C We transfected the proviral clones into C33A cells and analyzed the 5′ terminal sequence of the RNA transcripts by 5′ RACE. As a control, we identified the transcription initiation site for the original HIV-rtTA clone (TARm), which corresponds to the wild-type G+1 start (results not shown). Transcripts of the E mutant were also found to initiate at this G+1 residue or at the adjacent G+2 residue (Fig. (Fig.3D).3D The ER3 variant did not change the transcription initiation site (Fig. (Fig.3D).3D DISCUSSION The TAR hairpin, which is present at the 5′ and 3′ ends of the HIV-1 genomic and messenger RNAs, has been extensively studied in recent decades. The best-studied function of TAR is its essential role in the activation of transcription from the 5′ LTR promoter. Multiple studies in which replication of TAR-mutated HIV-1 variants in T-cell lines was analyzed suggested several additional functions of TAR in other processes during viral replication, including translation, dimerization, packaging, and reverse transcription. However, most of these studies are hampered by the fact that mutation of TAR significantly reduced Tat-mediated activation of transcription, which made it difficult to distinguish effects on other replication processes. In this study, we demonstrate that complete deletion of TAR does not abolish replication of an HIV-1 variant that does not require TAR for the activation of transcription. This result demonstrates that TAR has no essential function in HIV-1 replication other than to accommodate Tat-mediated activation of transcription. However, our studies focused on replication in T-cells and we cannot exclude the possibility that TAR may have an accessory function under specific conditions or in specific cell types in vivo. Our results suggest that efficient HIV-1 replication requires a stable stem-loop structure at the start of the viral transcripts, in which the 5′ terminal nucleotides are base paired. This structure can be the wild-type or truncated TAR hairpin (AB and CD mutants), the poly(A) hairpin (ER1 and ER2 variants), or a new stem-loop structure (ER3 variant), indicating that the nucleotide sequence of this 5′ hairpin is not important. These results are in agreement with a previous forced-evolution study in which HIV-1 replication was significantly reduced by opening of the lower TAR stem and strong evolutionary pressure restored the base pairing of this TAR region (21). Furthermore, structure analysis of multiple HIV-1, HIV-2, and simian immunodeficiency virus isolates revealed that the 5′ end of the RNA is always base paired, despite variations in overall leader and TAR structures (5). Whereas truncation of TAR in the double-mutated variants (AB and CD) had no effect on virus replication, destabilization of this stem-loop structure in the single-mutated variants (A, B, C, D, and F) blocked replication. The untranslated RNA leader region can fold either an extended duplex through long-distance base pairing (long-distance interaction) or a branched conformation in which the RNA locally folds into hairpin structures (branched multiple hairpin) (18). Although both conformations have the TAR hairpin, the unpaired nucleotides in the destabilized structure may interact with other regions of the leader and alter the long-distance interaction-branched multiple hairpin equilibrium and thus indirectly affect viral replication (18, 23). Similarly, the unpaired nucleotides present at the 5′ end of the transcripts of the E mutant may affect the leader structure and this may explain the reduced replication capacity of this variant. Alternatively, the presence of a stable stem-loop structure at the 5′ end of the transcripts may be important for RNA longevity, as previously described for bacterial and organelle mRNAs (12, 15, 31, 36). The TAR DNA sequence in the proviral 5′ LTR promoter region has been shown to bind various cellular transcription factors (reviewed in reference 25). We observed efficient replication of the evolved E variants in which TAR was replaced by nonrelated sequences or completely removed. Thus, although the binding of transcription factors to TAR DNA may be important for Tat-controlled transcription, these interactions are apparently not essential for virus replication in T cells when transcription is controlled by rtTA. During reverse transcription the sequence complementarity between the 5′ and 3′ R regions facilitates the first-strand transfer in which a cDNA copy of the 5′ R-U5 region (strong-stop minus-strand DNA) is translocated to the 3′ end of the viral RNA genome. Our results demonstrate that for this function the R region can be significantly shorter than the 97-nt wild-type element. The shortest R region, only 39 nt, is observed in the efficiently replicating ER2 variant. These results are in agreement with a previous study that demonstrated that strand transfer can be efficient with a minimal R-overlap region of approximately 30 nt (9). The dox-dependent HIV-rtTA variant was proposed as part of a novel strategy for development of a safe live attenuated HIV vaccine. In this study, we used HIV-rtTA to clarify the role of TAR in virus replication; the results demonstrated that this variant can also be a powerful tool to study HIV-1 biology. Acknowledgments We thank Stephan Heynen for CA-p24 ELISA. This research was sponsored by the Dutch AIDS Foundation (Aids Fonds grant 2005022), Technology Foundation STW (applied science division of NWO and the technology program of the Ministry of Economic Affairs, Utrecht, The Netherlands), ZON-Medical Sciences (MW; VICI grant), and NWO-Chemical Sciences (CW; TOP grant). Footnotes Published ahead of print on 9 May 2007.REFERENCES 1. Andersen, E. S., S. A. Contera, B. Knudsen, C. K. Damgaard, F. Besenbacher, and J. Kjems. 2004. Role of the trans-activation response element in dimerization of HIV-1 RNA. J. Biol. Chem. 279:22243-22249. [PubMed] 2. Bannwarth, S., and A. Gatignol. 2005. HIV-1 TAR RNA: the target of molecular interactions between the virus and its host. Curr. HIV Res. 3:61-71. [PubMed] 3. Bennasser, Y., S. Y. Le, M. L. Yeung, and K. T. Jeang. 2004. HIV-1 encoded candidate micro-RNAs and their cellular targets. Retrovirology 1:43. [PubMed] 4. Bennasser, Y., M. L. Yeung, and K. T. Jeang. 2006. HIV-1 TAR RNA subverts RNA interference in transfected cells through sequestration of TAR RNA-binding protein, TRBP. J. Biol. Chem. 281:27674-27678. [PubMed] 5. Berkhout, B. 1992. Structural features in TAR RNA of human and simian immunodeficiency viruses: a phylogenetic analysis. Nucleic Acids Res. 20:27-31. [PubMed] 6. Berkhout, B. 2000. Multiple biological roles associated with the repeat (R) region of the HIV-1 RNA genome. Adv. Pharmacol. 48:29-73. [PubMed] 7. Berkhout, B., B. Klaver, and A. T. Das. 1995. A conserved hairpin structure predicted for the poly(A) signal of human and simian immunodeficiency viruses. Virology 207:276-281. [PubMed] 8. Berkhout, B., R. H. Silverman, and K. T. Jeang. 1989. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 59:273-282. [PubMed] 9. Berkhout, B., J. van Wamel, and B. Klaver. 1995. Requirements for DNA strand transfer during reverse transcription in mutant HIV-1 virions. J. Mol. Biol. 252:59-69. [PubMed] 10. Bieniasz, P. D., T. A. Grdina, H. P. Bogerd, and B. R. Cullen. 1999. Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Proc. Natl. Acad. Sci. USA 96:7791-7796. [PubMed] 11. Brady, J., and F. Kashanchi. 2005. Tat gets the “green” light on transcription initiation. Retrovirology 2:69. [PubMed] 12. Bricker, A. L., and J. G. Belasco. 1999. Importance of a 5′ stem-loop for longevity of papA mRNA in Escherichia coli. J. Bacteriol. 181:3587-3590. [PubMed] 13. Das, A. T., K. Verhoef, and B. Berkhout. 2004. A conditionally replicating virus as a novel approach toward an HIV vaccine. Methods Enzymol. 388:359-379. [PubMed] 14. Das, A. T., X. Zhou, M. Vink, B. Klaver, K. Verhoef, G. Marzio, and B. Berkhout. 2004. Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J. Biol. Chem. 279:18776-18782. [PubMed] 15. Hambraeus, G., K. Karhumaa, and B. Rutberg. 2002. A 5′ stem-loop and ribosome binding but not translation are important for the stability of Bacillus subtilis aprE leader mRNA. Microbiology 148:1795-1803. [PubMed] 16. Harrich, D., C. W. Hooker, and E. Parry. 2000. The human immunodeficiency virus type 1 TAR RNA upper stem-loop plays distinct roles in reverse transcription and RNA packaging. J. Virol. 74:5639-5646. [PubMed] 17. Hirzmann, J., D. Luo, J. Hahnen, and G. Hobom. 1993. Determination of messenger RNA 5′-ends by reverse transcription of the cap structure. Nucleic Acids Res. 21:3597-3598. [PubMed] 18. Huthoff, H., and B. Berkhout. 2001. Mutations in the TAR hairpin affect the equilibrium between alternative conformations of the HIV-1 leader RNA. Nucleic Acids Res. 29:2594-2600. [PubMed] 19. Jeeninga, R. E., M. Hoogenkamp, M. Armand-Ugon, M. de Baar, K. Verhoef, and B. Berkhout. 2000. Functional differences between the long terminal repeat transcriptional promoters of HIV-1 subtypes A through G. J. Virol. 74:3740-3751. [PubMed] 20. Jeeninga, R. E., B. Jan, H. Van den Berg, and B. Berkhout. 2006. Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias. Retrovirology 3:64. [PubMed] 21. Klaver, B., and B. Berkhout. 1994. Evolution of a disrupted TAR RNA hairpin structure in the HIV-1 virus. EMBO J. 13:2650-2659. [PubMed] 22. Marzio, G., K. Verhoef, M. Vink, and B. Berkhout. 2001. In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies. Proc. Natl. Acad. Sci. USA 98:6342-6347. [PubMed] 23. Ooms, M., H. Huthoff, R. Russell, C. Liang, and B. Berkhout. 2004. A riboswitch regulates RNA dimerization and packaging in human immunodeficiency virus type 1 virions. J. Virol. 78:10814-10819. [PubMed] 24. Parada, C. A., and R. G. Roeder. 1996. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature 384:375-378. [PubMed] 25. Pereira, L. A., K. Bentley, A. Peeters, M. J. Churchill, and N. J. Deacon. 2000. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res. 28:663-668. [PubMed] 26. Raha, T., S. W. Cheng, and M. R. Green. 2005. HIV-1 Tat stimulates transcription complex assembly through recruitment of TBP in the absence of TAFs. PLoS Biol. 3:e44. [PubMed] 27. Richter, S., Y. H. Ping, and T. M. Rana. 2002. TAR RNA loop: a scaffold for the assembly of a regulatory switch in HIV replication. Proc. Natl. Acad. Sci. USA 99:7928-7933. [PubMed] 28. Rittner, K., M. J. Churcher, M. J. Gait, and J. Karn. 1995. The human immunodeficiency virus long terminal repeat includes a specialised initiator element which is required for Tat-responsive transcription. J. Mol. Biol. 248:562-580. [PubMed] 29. Ruijter, J. M., H. H. Thygesen, O. J. Schoneveld, A. T. Das, B. Berkhout, and W. H. Lamers. 2006. Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology 3:2. [PubMed] 30. Smith, S. M., M. Khoroshev, P. A. Marx, J. Orenstein, and K. T. Jeang. 2001. Constitutively dead, conditionally live HIV-1 genomes. Ex vivo implications for a live virus vaccine. J. Biol. Chem. 276:32184-32190. [PubMed] 31. Suay, L., M. L. Salvador, E. Abesha, and U. Klein. 2005. Specific roles of 5′ RNA secondary structures in stabilizing transcripts in chloroplasts. Nucleic Acids Res. 33:4754-4761. [PubMed] 32. Tan, R., A. Brodsky, J. R. Williamson, and A. D. Frankel. 1997. RNA recognition by HIV-1 Tat and Rev. Semin. Virol. 8:186-193. 33. Urlinger, S., U. Baron, M. Thellmann, M. T. Hasan, H. Bujard, and W. Hillen. 2000. Exploring the sequence space for tetracycline dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc. Natl. Acad. Sci. USA 97:7963-7968. [PubMed] 34. Verhoef, K., G. Marzio, W. Hillen, H. Bujard, and B. Berkhout. 2001. Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat. J. Virol. 75:979-987. [PubMed] 35. Wei, P., M. E. Garber, S.-M. Fang, W. H. Fisher, and K. A. Jones. 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451-462. [PubMed] 36. Zou, Z., C. Eibl, and H. U. Koop. 2003. The stem-loop region of the tobacco psbA 5′UTR is an important determinant of mRNA stability and translation efficiency. Mol. Genet. Genomics 269:340-349. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||
Cell. 1989 Oct 20; 59(2):273-82.
[Cell. 1989]Curr HIV Res. 2005 Jan; 3(1):61-71.
[Curr HIV Res. 2005]Retrovirology. 2005 Nov 9; 2():69.
[Retrovirology. 2005]Proc Natl Acad Sci U S A. 2002 Jun 11; 99(12):7928-33.
[Proc Natl Acad Sci U S A. 2002]Cell. 1998 Feb 20; 92(4):451-62.
[Cell. 1998]J Biol Chem. 2004 May 21; 279(21):22243-9.
[J Biol Chem. 2004]Curr HIV Res. 2005 Jan; 3(1):61-71.
[Curr HIV Res. 2005]Adv Pharmacol. 2000; 48():29-73.
[Adv Pharmacol. 2000]J Virol. 2000 Jun; 74(12):5639-46.
[J Virol. 2000]Retrovirology. 2004 Dec 15; 1():43.
[Retrovirology. 2004]Methods Enzymol. 2004; 388():359-79.
[Methods Enzymol. 2004]J Biol Chem. 2001 Aug 24; 276(34):32184-90.
[J Biol Chem. 2001]J Virol. 2001 Jan; 75(2):979-87.
[J Virol. 2001]Proc Natl Acad Sci U S A. 2000 Jul 5; 97(14):7963-8.
[Proc Natl Acad Sci U S A. 2000]Methods Enzymol. 2004; 388():359-79.
[Methods Enzymol. 2004]J Virol. 2001 Jan; 75(2):979-87.
[J Virol. 2001]Proc Natl Acad Sci U S A. 2001 May 22; 98(11):6342-7.
[Proc Natl Acad Sci U S A. 2001]J Biol Chem. 2004 Apr 30; 279(18):18776-82.
[J Biol Chem. 2004]J Virol. 2000 Apr; 74(8):3740-51.
[J Virol. 2000]J Biol Chem. 2004 Apr 30; 279(18):18776-82.
[J Biol Chem. 2004]Retrovirology. 2006 Jan 6; 3():2.
[Retrovirology. 2006]J Biol Chem. 2004 Apr 30; 279(18):18776-82.
[J Biol Chem. 2004]Retrovirology. 2006 Sep 27; 3():64.
[Retrovirology. 2006]J Mol Biol. 1995 Sep 8; 252(1):59-69.
[J Mol Biol. 1995]Virology. 1995 Feb 20; 207(1):276-81.
[Virology. 1995]J Mol Biol. 1995 May 5; 248(3):562-80.
[J Mol Biol. 1995]EMBO J. 1994 Jun 1; 13(11):2650-9.
[EMBO J. 1994]Nucleic Acids Res. 1992 Jan 11; 20(1):27-31.
[Nucleic Acids Res. 1992]Nucleic Acids Res. 2001 Jun 15; 29(12):2594-600.
[Nucleic Acids Res. 2001]J Virol. 2004 Oct; 78(19):10814-9.
[J Virol. 2004]J Bacteriol. 1999 Jun; 181(11):3587-90.
[J Bacteriol. 1999]Microbiology. 2002 Jun; 148(Pt 6):1795-803.
[Microbiology. 2002]Nucleic Acids Res. 2005; 33(15):4754-61.
[Nucleic Acids Res. 2005]Nucleic Acids Res. 2000 Feb 1; 28(3):663-8.
[Nucleic Acids Res. 2000]J Mol Biol. 1995 Sep 8; 252(1):59-69.
[J Mol Biol. 1995]Nucleic Acids Res. 1993 Jul 25; 21(15):3597-8.
[Nucleic Acids Res. 1993]